State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes
In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2440165 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122182810664960 |
|---|---|
| author | Elisa Tassinari Linda Danielli Andrea Marchetti Matteo Rosellini Costantino Ricci Pietro Piazza Angelo Mottaran Riccardo Schiavina Matteo Santoni Veronica Mollica Francesco Massari |
| author_facet | Elisa Tassinari Linda Danielli Andrea Marchetti Matteo Rosellini Costantino Ricci Pietro Piazza Angelo Mottaran Riccardo Schiavina Matteo Santoni Veronica Mollica Francesco Massari |
| author_sort | Elisa Tassinari |
| collection | DOAJ |
| description | In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC’s scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC. |
| format | Article |
| id | doaj-art-6a39bfc75398414b9d0c8f3b993328cc |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-6a39bfc75398414b9d0c8f3b993328cc2025-08-20T02:34:53ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2440165State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changesElisa Tassinari0Linda Danielli1Andrea Marchetti2Matteo Rosellini3Costantino Ricci4Pietro Piazza5Angelo Mottaran6Riccardo Schiavina7Matteo Santoni8Veronica Mollica9Francesco Massari10Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyPathology Unit, DIAP-Dipartimento InterAziendale di Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ItalyOncology Unit, Macerata Hospital, Macerata, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyIn recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC’s scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC.https://www.tandfonline.com/doi/10.1080/21645515.2024.2440165Urothelial cancerbladder canceradjuvant therapyimmunotherapymuscle-invasive bladder cancernon-muscle invasive bladder cancer |
| spellingShingle | Elisa Tassinari Linda Danielli Andrea Marchetti Matteo Rosellini Costantino Ricci Pietro Piazza Angelo Mottaran Riccardo Schiavina Matteo Santoni Veronica Mollica Francesco Massari State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes Human Vaccines & Immunotherapeutics Urothelial cancer bladder cancer adjuvant therapy immunotherapy muscle-invasive bladder cancer non-muscle invasive bladder cancer |
| title | State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes |
| title_full | State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes |
| title_fullStr | State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes |
| title_full_unstemmed | State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes |
| title_short | State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes |
| title_sort | state of the art of adjuvant immunotherapy in urothelial cancer new developments and upcoming changes |
| topic | Urothelial cancer bladder cancer adjuvant therapy immunotherapy muscle-invasive bladder cancer non-muscle invasive bladder cancer |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2440165 |
| work_keys_str_mv | AT elisatassinari stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT lindadanielli stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT andreamarchetti stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT matteorosellini stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT costantinoricci stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT pietropiazza stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT angelomottaran stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT riccardoschiavina stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT matteosantoni stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT veronicamollica stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges AT francescomassari stateoftheartofadjuvantimmunotherapyinurothelialcancernewdevelopmentsandupcomingchanges |